Cowen Maintains Neutral View on Sarepta (SRPT) Despite Rolling NDA for Eteplirsen

WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital Says

Roth Capital analyst Debjit Chattopadhyay is taking exception to the bearish article published in the WSJ about Sarepta Therapeutic (NASDAQ: SRPT) which compared the company to its mature peer BioMarin (NASDAQ: BMRN) on a 2016 price/sales metric.... More

BofA/Merrill Lynch Downgrades Sarepta Therapeutic (SRPT) to Neutral

BofA/Merrill Lynch downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Neutral with a price target of $28.00 (from $20.00). Yesterday the company announced it will initiate a rolling NDA for eteplirsen. Analyst Steve Byrne sees 60% (prior 50%) probability of eteplirsen approval, buy he now sees... More

Sarepta Therapeutic (SRPT) Has 100% Upside, 50% Downside - Deutsche Bank

Deutsche Bank maintained a Hold rating on Sarepta Therapeutic (NASDAQ: SRPT) with a price target of $24. Yesterday Sarepta said it will initiate a rolling NDA submission for eteplirsen. Analyst Robyn Karnauskas sees 100% upside and 50% downside in the stock, depending on the FDA's decision.

"We see this as incrementally positive, as the company is sticking with previous guidance of a mid-2015 submission. We note this is only the... More

Sarepta (SRPT) PT Raised to $25 at Wedbush on Go-Ahead for Eteplirsen NDA

Wedbush analyst Heather Behanna raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $25.00 (from $16.00) after the company announced it has been given the go-ahead for a rolling NDA submission for eteplirsen with filing to be complete midyear. The firm, however, stopped short of upgrading the stock and maintained a Neutral... More

Piper Jaffray Remains on Sidelines with Sarepta (SRPT) Despite Rolling NDA For Eteplirsen

Piper Jaffray analyst Edward Tenthoff reiterated a Neutral rating and $20 price target on Sarepta Therapeutic (NASDAQ: SRPT) after announcing it will move forward with a rolling NDA submission for Eteplirsen. The company expects to submit preclinical and CMC data by the end of... More

UPDATE: Canaccord Genuity Upgrades Sarepta Therapeutic (SRPT) to Buy

(Updated - May 20, 2015 10:26 AM EDT)

Canaccord Genuity upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Hold to Buy with a price target of $30.00 (from $16.00). Yesterday Sarepta said, after meeting with the FDA, it will initiate a rolling NDA submission for eteplirsen and will submit... More

SunTrust Upgrades Sarepta Therapeutic (SRPT) to Buy

SunTrust Robinson Humphrey upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Buy with a price target of $33.00 (from $14.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $16.38 yesterday.

Sarepta Therapeutic (SRPT) PT Raised to $45 at Roth Capital

Roth Capital analyst Debjit Chattopadhyay reiterated a Buy and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $45.00 (from $22.00) following the rolling NDA submission with the FDA for eteplirsen.

Chattopadhyay commented, "Sarepta's meeting with the FDA has culminated into a... More

Sarepta (SRPT) PT Boosted to $34 at Baird Amid Rolling NDA Submission

Baird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $34.00 (from $20.00) following news of a rolling NDA submission with the FDA for eteplirsen.

Skorney commented, "As envisioned in our upgrade note earlier... More

Sarepta Therapeutics (SRPT) Will Initiate Rolling NDA for Eteplirsen

Sarepta Therapeutics (NASDAQ: SRPT) announced that the Company held a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding its lead product candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD). Sarepta has agreed with the... More